IL295914B2 - Evacuated blood collection tubes containing protease inhibitors for the assessment of contact system activation - Google Patents

Evacuated blood collection tubes containing protease inhibitors for the assessment of contact system activation

Info

Publication number
IL295914B2
IL295914B2 IL295914A IL29591422A IL295914B2 IL 295914 B2 IL295914 B2 IL 295914B2 IL 295914 A IL295914 A IL 295914A IL 29591422 A IL29591422 A IL 29591422A IL 295914 B2 IL295914 B2 IL 295914B2
Authority
IL
Israel
Prior art keywords
contact system
drug
subject
blood collection
protease inhibitors
Prior art date
Application number
IL295914A
Other languages
English (en)
Hebrew (he)
Other versions
IL295914B1 (en
IL295914A (en
Original Assignee
Takeda Pharmaceuticals Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceuticals Co filed Critical Takeda Pharmaceuticals Co
Publication of IL295914A publication Critical patent/IL295914A/en
Publication of IL295914B1 publication Critical patent/IL295914B1/en
Publication of IL295914B2 publication Critical patent/IL295914B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/15—Devices for taking samples of blood
    • A61B5/153—Devices specially adapted for taking samples of venous or arterial blood, e.g. with syringes
    • A61B5/154—Devices using pre-evacuated means
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/15—Devices for taking samples of blood
    • A61B5/150007—Details
    • A61B5/150015—Source of blood
    • A61B5/15003—Source of blood for venous or arterial blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/15—Devices for taking samples of blood
    • A61B5/150007—Details
    • A61B5/150755—Blood sample preparation for further analysis, e.g. by separating blood components or by mixing
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L3/00—Containers or dishes for laboratory use, e.g. laboratory glassware; Droppers
    • B01L3/50—Containers for the purpose of retaining a material to be analysed, e.g. test tubes
    • B01L3/508—Rigid containers without fluid transport within
    • B01L3/5082—Test tubes per se
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/96—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood or serum control standard
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L2200/00—Solutions for specific problems relating to chemical or physical laboratory apparatus
    • B01L2200/16—Reagents, handling or storing thereof
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L2300/00—Additional constructional details
    • B01L2300/08—Geometry, shape and general structure
    • B01L2300/0832—Geometry, shape and general structure cylindrical, tube shaped
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
    • G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
    • G01N2333/96433—Serine endopeptidases (3.4.21)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Public Health (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Surgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medical Informatics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Clinical Laboratory Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Rehabilitation Therapy (AREA)
  • Rheumatology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measurement Of The Respiration, Hearing Ability, Form, And Blood Characteristics Of Living Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL295914A 2015-08-13 2016-08-12 Evacuated blood collection tubes containing protease inhibitors for the assessment of contact system activation IL295914B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562204644P 2015-08-13 2015-08-13
US201562214308P 2015-09-04 2015-09-04
PCT/US2016/046681 WO2017027771A1 (en) 2015-08-13 2016-08-12 Evacuated blood collection tubes containing protease inhibitors for the assessment of contact system activation

Publications (3)

Publication Number Publication Date
IL295914A IL295914A (en) 2022-10-01
IL295914B1 IL295914B1 (en) 2024-05-01
IL295914B2 true IL295914B2 (en) 2024-09-01

Family

ID=56802683

Family Applications (3)

Application Number Title Priority Date Filing Date
IL295914A IL295914B2 (en) 2015-08-13 2016-08-12 Evacuated blood collection tubes containing protease inhibitors for the assessment of contact system activation
IL311909A IL311909B2 (en) 2015-08-13 2016-08-12 Method for assessing the level of a drug directed to a contact system in a subject
IL257209A IL257209B (en) 2015-08-13 2016-08-12 Test tubes for blood collection that include protease inhibitors to assess the activation of the contact system

Family Applications After (2)

Application Number Title Priority Date Filing Date
IL311909A IL311909B2 (en) 2015-08-13 2016-08-12 Method for assessing the level of a drug directed to a contact system in a subject
IL257209A IL257209B (en) 2015-08-13 2016-08-12 Test tubes for blood collection that include protease inhibitors to assess the activation of the contact system

Country Status (13)

Country Link
US (3) US10870115B2 (https=)
EP (3) EP3909509B1 (https=)
JP (4) JP6907188B2 (https=)
KR (2) KR102777762B1 (https=)
CN (2) CN116196995A (https=)
AU (2) AU2016306653B2 (https=)
BR (1) BR112018002742B1 (https=)
CO (1) CO2018002531A2 (https=)
EA (1) EA201890478A1 (https=)
ES (1) ES2938089T3 (https=)
IL (3) IL295914B2 (https=)
MX (2) MX2018001786A (https=)
WO (1) WO2017027771A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6907188B2 (ja) 2015-08-13 2021-07-21 ダイアックス コーポレーション 接触系活性化の評価のためのプロテアーゼ阻害剤を含む真空採血管
US11340237B2 (en) 2016-09-16 2022-05-24 Takeda Pharmaceutical Company Limited Metabolite biomarkers for diseases associated with the contact activation system
EP4548103A2 (en) 2022-06-30 2025-05-07 Takeda Pharmaceutical Company Limited Protein biomarkers for lanadelumab treatment

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003097237A2 (en) * 2002-05-13 2003-11-27 Becton, Dickinson, And Company Protease inhibitor sample collection system
CN102596179A (zh) * 2009-08-27 2012-07-18 工业研究与发展基金会有限公司 脂质体组合物及其用途

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5047323A (en) 1986-01-22 1991-09-10 Temple University Of The Commonwealth System Of Higher Education Method for detecting human kininogen using monoclonal antibodies thereto
WO1995021601A2 (en) 1994-01-11 1995-08-17 Protein Engineering Corporation Kallikrein-inhibiting 'kunitz domain' proteins and analogues thereof
JP3622286B2 (ja) * 1995-09-01 2005-02-23 日東紡績株式会社 α２ −プラスミンインヒビタ−の測定方法及び測定試 薬
US5789261A (en) * 1996-10-30 1998-08-04 Temple University Of The Commonwealth System Of Higher Education Solid phase immunoassay
SK12572001A3 (sk) * 1999-03-15 2002-03-05 Takeda Chemical Industries, Ltd. Proteín, peptid, protilátka, spôsob výroby a farmaceutický prostriedok
SE0202880D0 (sv) * 2002-07-26 2002-09-30 Wieslab Ab Complement system deficiency assay
US8603345B2 (en) * 2003-02-13 2013-12-10 Becton, Dickinson And Company Devices for component removal during blood collection, and uses thereof
US7138412B2 (en) 2003-03-11 2006-11-21 Bristol-Myers Squibb Company Tetrahydroquinoline derivatives useful as serine protease inhibitors
US20050124965A1 (en) * 2003-12-08 2005-06-09 Becton, Dickinson And Company Phosphatase inhibitor sample collection system
WO2005084317A2 (en) * 2004-03-01 2005-09-15 Board Of Regents, The University Of Texas System Dimeric small molecule potentiators of apoptosis
EP1828152B1 (en) 2004-12-08 2008-08-20 Bristol-Myers Squibb Company Heterocyclic compounds as inhibitors of factor viia
US20060183771A1 (en) 2005-02-17 2006-08-17 Seiffert Dietmar A Novel combination of selective factor VIIa and/or factor XIa inhibitors and selective plasma kallikrein inhibitors
US9957569B2 (en) * 2005-09-12 2018-05-01 The Regents Of The University Of Michigan Recurrent gene fusions in prostate cancer
ES2336622T3 (es) 2006-06-06 2010-04-14 F. Hoffmann-La Roche Ag Recipiente de recogida de sangre total lista para usar.
EP1890155A1 (en) * 2006-08-17 2008-02-20 F. Hoffmann-Roche AG Methods and means for determining platelet function and diagnosing platelet-related and cardiovascular disorders
US20080286818A1 (en) * 2007-05-18 2008-11-20 Datwyler Saul A Blood sample handling methods for improved assays for myeloperoxidase
JP2010528647A (ja) * 2007-06-06 2010-08-26 ドマンティス リミテッド ポリペプチド、抗体可変ドメインおよびアンタゴニスト
WO2009022001A1 (en) * 2007-08-16 2009-02-19 Novartis Ag Improvement of drug tolerance in immunogenicity testing
WO2009026539A1 (en) * 2007-08-23 2009-02-26 Genzyme Corporation Treatment with kallikrein inhibitors
US8283160B2 (en) * 2007-09-11 2012-10-09 Frey Ii William H Methods, pharmaceutical compositions and articles of manufacture for administering therapeutic cells to the animal central nervous system
US9482677B2 (en) 2008-02-27 2016-11-01 Scios Inc. Method, composition and device for sampling natriuretic peptides in a biological fluid
US7985188B2 (en) 2009-05-13 2011-07-26 Cv Holdings Llc Vessel, coating, inspection and processing apparatus
WO2011033046A1 (en) 2009-09-18 2011-03-24 Probiodrug Ag Novel assay for the detection of amyloid beta peptides
CN102740888B (zh) * 2009-11-24 2016-10-12 奥尔德生物制药公司 Il-6抗体及其用途
NZ609363A (en) 2010-10-18 2015-04-24 Nestec Sa Methods for determining anti-drug antibody isotypes
KR102320178B1 (ko) * 2011-01-06 2021-11-02 다케다 파머수티컬 컴패니 리미티드 혈장 칼리크레인 결합 단백질
CA2828761C (en) 2011-03-04 2017-04-04 Becton, Dickinson And Company Blood collection device containing lysophospholipase inhibitor
JP6189754B2 (ja) * 2011-03-04 2017-08-30 イントレキソン コーポレーション タンパク質を条件的に発現するベクター
US9352016B2 (en) * 2011-03-09 2016-05-31 Csl Behring Gmbh Factor XII inhibitors for the administration with medical procedures comprising contact with artificial surfaces
GB201114017D0 (en) 2011-08-15 2011-09-28 Univ Dundee Inhibitors against endosomal/ysosomal enzymes
BR112014018970A8 (pt) * 2012-02-02 2017-07-11 Becton Dickinson Co Dispositivos de coleta de amostra com agentes de estabilização sanguínea
RU2015136025A (ru) 2013-02-01 2017-03-06 Бектон, Дикинсон энд Кампани Устройства для сбора крови, содержащие добавки, ингибирующие контактный путь свертывания крови
CA2916399C (en) 2013-06-28 2022-08-02 Marc Nolte Combination therapy using a factor xii inhibitor and a c1-inhibitor
WO2015061183A1 (en) 2013-10-21 2015-04-30 Dyax Corp. Assays for determining plasma kallikrein system biomarkers
JP6907188B2 (ja) * 2015-08-13 2021-07-21 ダイアックス コーポレーション 接触系活性化の評価のためのプロテアーゼ阻害剤を含む真空採血管

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003097237A2 (en) * 2002-05-13 2003-11-27 Becton, Dickinson, And Company Protease inhibitor sample collection system
CN102596179A (zh) * 2009-08-27 2012-07-18 工业研究与发展基金会有限公司 脂质体组合物及其用途

Also Published As

Publication number Publication date
JP7829634B2 (ja) 2026-03-13
JP6907188B2 (ja) 2021-07-21
CN108135547A (zh) 2018-06-08
JP7242765B2 (ja) 2023-03-20
JP2023078232A (ja) 2023-06-06
NZ739623A (en) 2023-09-29
US20190022641A1 (en) 2019-01-24
EP4574040A2 (en) 2025-06-25
AU2021215261B2 (en) 2023-10-12
EA201890478A1 (ru) 2018-07-31
IL257209B (en) 2022-09-01
IL311909B1 (en) 2025-11-01
HK1255461A1 (en) 2019-08-16
WO2017027771A1 (en) 2017-02-16
CO2018002531A2 (es) 2018-06-12
EP3334343B1 (en) 2022-10-19
KR102777762B1 (ko) 2025-03-11
IL295914B1 (en) 2024-05-01
KR20250035045A (ko) 2025-03-11
US20230182139A1 (en) 2023-06-15
JP2024150720A (ja) 2024-10-23
BR112018002742B1 (pt) 2023-05-16
EP3909509A1 (en) 2021-11-17
EP4574040A3 (en) 2025-08-27
ES2938089T3 (es) 2023-04-04
AU2016306653A1 (en) 2018-02-22
CN108135547B (zh) 2023-01-10
IL257209A (en) 2018-04-30
MX2022014713A (es) 2022-12-16
US10870115B2 (en) 2020-12-22
IL311909B2 (en) 2026-03-01
IL311909A (en) 2024-06-01
MX2018001786A (es) 2018-06-06
US11826758B2 (en) 2023-11-28
EP3909509B1 (en) 2025-04-09
EP3334343A1 (en) 2018-06-20
US11458477B2 (en) 2022-10-04
AU2016306653B2 (en) 2021-05-13
CN116196995A (zh) 2023-06-02
US20210322972A1 (en) 2021-10-21
AU2021215261A1 (en) 2021-09-02
BR112018002742A2 (https=) 2018-10-02
CA2995457A1 (en) 2017-02-16
JP2018532100A (ja) 2018-11-01
JP2021164678A (ja) 2021-10-14
IL295914A (en) 2022-10-01
KR20180100107A (ko) 2018-09-07

Similar Documents

Publication Publication Date Title
US11826758B2 (en) Evacuated blood collection tubes containing protease inhibitors for the assessment of contact system activation
AU2022204058B2 (en) Peptide quantitation assay for differentiating full-length high molecular weight kininogen (HMWK) and cleaved HMWK
CA2995457C (en) Evacuated blood collection tubes containing protease inhibitors for the assessment of contact system activation
HK40128524A (en) Evacuated blood collection tubes containing protease inhibitors for the assessment of contact system activation
HK40061902A (en) Evacuated blood collection tubes containing protease inhibitors for the assessment of contact system activation
HK40061902B (en) Evacuated blood collection tubes containing protease inhibitors for the assessment of contact system activation
EA040036B1 (ru) Вакуумные пробирки для сбора крови, содержащие ингибиторы протеазы, для оценки активации контактной системы
HK1255461B (en) Evacuated blood collection tubes containing protease inhibitors for the assessment of contact system activation
NZ739623B2 (en) Evacuated blood collection tubes containing protease inhibitors for the assessment of contact system activation